Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Trisomy 21 is a common congenital disorder with well-documented clinical manifestations, including an increased risk for the transient myeloproliferative disorder as a neonate and leukemia in childhood and adolescence. Transient myeloproliferative disorder is only known to occur in hematopoietic cells with trisomy 21. Children with mosaic trisomy 21 also have a risk for hematological malignancies. We present a nondysmorphic neonate, with a negative noninvasive prenatal screening of maternal blood for trisomy 21, who came to medical attention because of ruddy skin. He was found to have mild polycythemia, thrombocytopenia, and developed peripheral blasts. His clinical presentation was consistent with transient myeloproliferative disorder, which is only seen with trisomy 21. Cytogenetic studies of peripheral blood are positive for mosaic trisomy 21.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751406PMC
http://dx.doi.org/10.1101/mcs.a006126DOI Listing

Publication Analysis

Top Keywords

transient myeloproliferative
16
myeloproliferative disorder
16
mosaic trisomy
12
trisomy
7
disorder
5
transient
4
disorder presenting
4
presenting feature
4
feature mosaic
4
trisomy trisomy
4

Similar Publications

Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by abnormal megakaryocyte proliferation and a markedly elevated platelet count, which predisposes patients to thrombotic or hemorrhagic events. Approximately 50%-60% of ET patients harbor a JAK2 V617F mutation. This mutation drives constitutive JAK kinase activation, promoting megakaryocyte proliferation and platelet production, while potentially activating inflammatory pathways and damaging vascular endothelium.

View Article and Find Full Text PDF

: The relationship between spleen and bone marrow stiffness, and other features of abnormal myeloproliferation has long been described. However, the scientific knowledge in this area remains very superficial. This review evaluated the diagnostic effectiveness of various ultrasound (US) methods in the assessment of neoplastic myeloproliferation using spleen stiffness measurement (SSM).

View Article and Find Full Text PDF

Translational Insights into Interferon Alpha's Effects on Immunomolecular Dynamics in Philadelphia-Negative Myeloproliferative Neoplasms.

Cancers (Basel)

July 2025

BE21-Hematología e Inmunoterapia, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), 29071 Malaga, Spain.

Interferon alpha (IFNα) remains a cornerstone in the management of Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPNs), yet its immunomolecular impact over time is not fully elucidated. The aim of the study was to explore how IFNα therapy dynamically reshapes immune and gene profiles in Ph-neg MPNs and assess their potential as treatment-related biomarkers. This single-center, prospective, observational study included a translational substudy conducted within a previously established clinical cohort of 44 IFNα-treated patients, selecting a representative subset of 18 individuals stratified by treatment duration.

View Article and Find Full Text PDF

Gestational alloimmune liver disease (GALD) is a leading cause of neonatal acute liver failure (ALF) with unique histologic features but no established histologic scoring criteria. This study aimed to develop an accurate histologic scoring system to distinguish GALD from non-GALD neonatal ALF. A preliminary system using 6 histologic features characteristic of GALD was created.

View Article and Find Full Text PDF

Transient abnormal myelopoiesis in a premature infant with Down syndrome: A case report.

Medicine (Baltimore)

July 2025

Department of Neonatology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei Province, China.

Rationale: Transient abnormal myelopoiesis with mutations in GATA1 gene can be self-alleviated after 3 to 4 months of birth in term infant, however, the premature infant with this disease in our research achieved remission earlier.

Patient Concerns: A 10-hours-old girl was diagnosed with transient abnormal myelopoiesis with GATA1 mutation.

Diagnosis: Transient abnormal myelopoiesis in a premature infant was suspected.

View Article and Find Full Text PDF